Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), Aurinia Pharmaceuticals (AUPH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGNDResearch Report), Aurinia Pharmaceuticals (AUPHResearch Report) and Diffusion Pharmaceuticals Inc (DFFNResearch Report) with bullish sentiments.

Ligand Pharma (LGND)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma, with a price target of $254. The company’s shares closed yesterday at $124.02, close to its 52-week low of $98.56.

According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.9% and a 29.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ligand Pharma with a $224.67 average price target, an 81.2% upside from current levels. In a report issued on March 7, Roth Capital also reiterated a Buy rating on the stock with a $180 price target.

See today’s analyst top recommended stocks >>

Aurinia Pharmaceuticals (AUPH)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $15. The company’s shares closed yesterday at $6.42.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 10.2% and a 45.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.

Currently, the analyst consensus on Aurinia Pharmaceuticals is a Moderate Buy with an average price target of $19.50, implying a 203.7% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $24 price target.

Diffusion Pharmaceuticals Inc (DFFN)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Diffusion Pharmaceuticals Inc today and set a price target of $10. The company’s shares closed yesterday at $4.70.

Ramakanth wrote:

“We maintain our Buy rating of DFFN and adjust our 12- month price target to $10.00 per share from $1.25. We derive our price target based on a risk-adjusted NPV analysis of projected TSC revenues through 2030 assuming a 12% discount rate and 2% terminal growth rate.”

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.3% and a 36.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Gritstone Oncology Inc, Trillium Therapeutics, and Tyme Technologies Inc.

The the analyst consensus on Diffusion Pharmaceuticals Inc is currently a Hold rating.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Leave a Reply

Your email address will not be published. Required fields are marked *